Published in Proc Natl Acad Sci U S A on February 01, 2010
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci U S A (2011) 2.03
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe (2013) 1.95
A research agenda for malaria eradication: basic science and enabling technologies. PLoS Med (2011) 1.89
The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 1.69
Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology (2014) 1.61
Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem (2010) 1.58
Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol (2013) 1.49
Hepatitis C virus: assembly and release of virus particles. J Biol Chem (2010) 1.42
Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv (2014) 1.33
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab (2011) 1.27
Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology (2012) 1.21
Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe (2014) 1.19
Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol (2011) 1.17
New horizons for studying human hepatotropic infections. J Clin Invest (2010) 1.16
Cell and tissue engineering for liver disease. Sci Transl Med (2014) 1.08
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. Proc Natl Acad Sci U S A (2014) 1.07
Organ-on-a-chip platforms for studying drug delivery systems. J Control Release (2014) 1.06
Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. Virology (2013) 1.01
Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest (2014) 0.97
Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol (2012) 0.97
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis (2012) 0.94
Modulation of apoptotic signaling by the hepatitis B virus X protein. Viruses (2012) 0.93
Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure. Exp Biol Med (Maywood) (2014) 0.93
Innate host response in primary human hepatocytes with hepatitis C virus infection. PLoS One (2011) 0.93
Barriers of hepatitis C virus interspecies transmission. Virology (2013) 0.92
Modulating innate immunity improves hepatitis C virus infection and replication in stem cell-derived hepatocytes. Stem Cell Reports (2014) 0.89
Long-term culture and expansion of primary human hepatocytes. Nat Biotechnol (2015) 0.87
Hepatitis C virus experimental model systems and antiviral drug research. Virol Sin (2010) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Animal models for the study of HCV. Curr Opin Virol (2015) 0.86
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice. Hepatology (2015) 0.86
Permissiveness of human hepatoma cell lines for HCV infection. Virol J (2012) 0.86
Dissecting the roles of the 5' exoribonucleases Xrn1 and Xrn2 in restricting hepatitis C virus replication. J Virol (2015) 0.86
Hepatitis C virus assembly imaging. Viruses (2011) 0.85
Visualizing hepatitis C virus infection in humanized mice. J Immunol Methods (2014) 0.82
In vitro systems for the study of hepatitis C virus infection. Int J Hepatol (2012) 0.82
HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Res Ther (2013) 0.81
Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PLoS One (2013) 0.81
Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) (2015) 0.81
MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells. PLoS One (2014) 0.81
New Methods in Tissue Engineering: Improved Models for Viral Infection. Annu Rev Virol (2014) 0.81
Hormone and Drug-Mediated Modulation of Glucose Metabolism in a Microscale Model of the Human Liver. Tissue Eng Part C Methods (2015) 0.81
Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Dig Dis Sci (2015) 0.81
Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. PLoS Comput Biol (2011) 0.80
Prominent steatosis with hypermetabolism of the cell line permissive for years of infection with hepatitis C virus. PLoS One (2014) 0.80
Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. Front Immunol (2014) 0.80
MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a. PLoS One (2014) 0.80
Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection. Nat Chem Biol (2016) 0.79
Ex vivo gene delivery to hepatocytes: techniques, challenges, and underlying mechanisms. Ann Biomed Eng (2012) 0.79
Microphysical space of a liver sinusoid device enables simplified long-term maintenance of chimeric mouse-expanded human hepatocytes. Biomed Microdevices (2014) 0.79
Physiologically relevant human tissue models for infectious diseases. Drug Discov Today (2016) 0.77
Experimental models of hepatitis B and C - new insights and progress. Nat Rev Gastroenterol Hepatol (2016) 0.76
The missing pieces of the HCV entry puzzle. Future Virol (2015) 0.76
New hepatitis C virus drug discovery strategies and model systems. Expert Opin Drug Discov (2012) 0.76
Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses (2015) 0.75
Getting closer to the patient: upgrade of hepatitis C virus infection in primary human hepatocytes. J Hepatol (2010) 0.75
Engineered Liver Platforms for Different Phases of Drug Development. Trends Biotechnol (2016) 0.75
Profile of Charles M. Rice. Proc Natl Acad Sci U S A (2011) 0.75
Proteomic approaches to analyzing hepatitis C virus biology. Proteomics (2015) 0.75
Genetic Dissection of the Host Tropism of Human-Tropic Pathogens. Annu Rev Genet (2015) 0.75
Advances and Challenges in Studying Hepatitis B Virus In Vitro. Viruses (2016) 0.75
Long-term hepatitis B infection in a scalable hepatic co-culture system. Nat Commun (2017) 0.75
Characterization of miR-122-independent propagation of HCV. PLoS Pathog (2017) 0.75
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Microscale culture of human liver cells for drug development. Nat Biotechnol (2007) 4.85
Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 4.58
Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J (1999) 4.22
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol (2000) 3.26
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol (2007) 2.18
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (1993) 1.84
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos (2003) 1.66
A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab (2005) 1.61
Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci (2001) 1.59
Focal distribution of hepatitis C virus RNA in infected livers. PLoS One (2009) 1.32
In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J Gen Virol (1998) 1.23
Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol (1999) 1.13
Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One (2008) 1.09
Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology (2004) 1.04
Replication and multiplication of hepatitis C virus genome in human foetal liver cells. Res Virol (1993) 0.95
Susceptibility of human liver cell cultures to hepatitis C virus infection. Arch Virol Suppl (1993) 0.91
Going towards more relevant cell culture models to study the in vitro replication of serum-derived hepatitis C virus and virus/host cell interactions? J Hepatol (2006) 0.84
Expression of hTERT mRNA in a mortal liver cell line during S phase without detectable telomerase activity. Int J Mol Med (2005) 0.82
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
A diverse range of gene products are effectors of the type I interferon antiviral response. Nature (2011) 12.86
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A (2002) 5.35
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Microscale culture of human liver cells for drug development. Nat Biotechnol (2007) 4.85
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater (2009) 4.77
Molecular biology of flaviviruses. Adv Virus Res (2003) 4.39
An extracellular matrix microarray for probing cellular differentiation. Nat Methods (2005) 4.35
Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol (2007) 4.28
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater (2012) 4.10
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature (2005) 3.83
Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83
Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res (2009) 3.77
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Micromechanical control of cell-cell interactions. Proc Natl Acad Sci U S A (2007) 3.53
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol (2011) 3.44
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci U S A (2002) 3.21
Probing the role of multicellular organization in three-dimensional microenvironments. Nat Methods (2006) 3.20
Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol (2003) 3.19
The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem (2004) 3.15
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Biomolecular screening with encoded porous-silicon photonic crystals. Nat Mater (2002) 3.13
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol (2002) 3.07
Fabrication of 3D hepatic tissues by additive photopatterning of cellular hydrogels. FASEB J (2006) 2.95
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A (2004) 2.77
The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 2.68
Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol (2007) 2.65
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature (2006) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection. J Virol (2002) 2.55
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog (2010) 2.48
Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol (2007) 2.45
euHCVdb: the European hepatitis C virus database. Nucleic Acids Res (2006) 2.41
MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature (2013) 2.40
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology (2004) 2.37
A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol (2004) 2.36
Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 2.31
Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem (2007) 2.31
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol (2003) 2.25
Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 2.20
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small (2009) 2.16
Characterization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci U S A (2011) 2.14
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A (2012) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 2.06
Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science (2012) 2.06
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci U S A (2011) 2.03
Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. Adv Mater (2008) 2.01
Tracking and elucidating alphavirus-host protein interactions. J Biol Chem (2006) 2.01